Literature DB >> 16115026

PKC alpha depletion in RAW264.7 macrophages following microbial/IFNgamma stimulation is PC-PLC-mediated.

Andreas von Knethen1, Bernhard Brüne.   

Abstract

Under chronic inflammatory conditions, monocytes/macrophages often exhibit a desensitized phenotype, which is characterized by attenuated reactive oxygen species (ROS) production in close association with depletion of protein kinase C alpha (PKC alpha). This behavior has been observed in monocytes derived from septic blood although the stimulus responsible for initiating these alterations remained obscure. Using RAW264.7 macrophages, we provide evidence that components of neither gram-negative nor gram-positive bacteria deplete PKC alpha, whereas the T(H)1 cytokine interferon-gamma (IFNgamma) does. As shown by western blot analysis, lipopolysaccharide, as well as lipoteichoic acid, did not alter PKC alpha expression, but IFNgamma dose-dependently decreased PKC alpha protein level. Taking into consideration that diacylglycerol and Ca2+ as established PKC alpha activators are released in response to phospholipase C activation, we pretreated cells with the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor tricyclodecan-9-yl potassium xanthate (D609) and the phosphatidylinositol-specific phospholipase C inhibitor 1-(6-(17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U73122). In cells preincubated with D609, IFNgamma-mediated PKC alpha depletion was attenuated, whereas U73122 did not impair this process. Moreover, phorbol 12-myristate 13-acetate-initiated ROS formation, which was attenuated in macrophages pretreated with IFNgamma, was restored in the presence of the PC-PLC inhibitor. These results suggest that IFNgamma causes PC-PLC stimulation, diacylglycerol release, Ca2+ influx, and concomitant PKC alpha activation, which subsequently depletes PKC alpha. Strategies to antagonize IFNgamma might be helpful to prevent monocyte/macrophage desensitization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115026     DOI: 10.1089/ars.2005.7.1217

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  6 in total

1.  Silica induces macrophage cytokines through phosphatidylcholine-specific phospholipase C with hydrogen peroxide.

Authors:  Honglei Liu; Hongqiao Zhang; Henry Jay Forman
Journal:  Am J Respir Cell Mol Biol       Date:  2006-12-07       Impact factor: 6.914

2.  Positive correlation between PEDF expression levels and macrophage density in the human prostate.

Authors:  Thomas Nelius; Christina Samathanam; Dalia Martinez-Marin; Natalie Gaines; Jessica Stevens; Johnny Hickson; Werner de Riese; Stéphanie Filleur
Journal:  Prostate       Date:  2012-10-04       Impact factor: 4.104

3.  An Evolutionarily Conserved PLC-PKD-TFEB Pathway for Host Defense.

Authors:  Mehran Najibi; Sid Ahmed Labed; Orane Visvikis; Javier Elbio Irazoqui
Journal:  Cell Rep       Date:  2016-05-12       Impact factor: 9.423

4.  Quantitation of spin probe-detectable oxidants in cells using electron paramagnetic resonance spectroscopy: To probe or to trap?

Authors:  John P Gotham; Rui Li; Trent E Tipple; Jack R Lancaster; Taiming Liu; Qian Li
Journal:  Free Radic Biol Med       Date:  2020-05-04       Impact factor: 7.376

5.  A NOVEL NOX/PHOX-CD38-NAADP-TFEB AXIS IMPORTANT FOR MACROPHAGE ACTIVATION DURING BACTERIAL PHAGOCYTOSIS.

Authors:  Mehran Najibi; Havisha H Honwad; Joseph A Moreau; Stephanie M Becker; Javier E Irazoqui
Journal:  Autophagy       Date:  2021-04-13       Impact factor: 16.016

6.  Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted Therapy.

Authors:  Franca Podo; Luisa Paris; Serena Cecchetti; Francesca Spadaro; Laura Abalsamo; Carlo Ramoni; Alessandro Ricci; Maria Elena Pisanu; Francesco Sardanelli; Rossella Canese; Egidio Iorio
Journal:  Front Oncol       Date:  2016-08-02       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.